Breast Implants Lymphoma Cancer
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The Law Offices of Thomas J. Lamb represents people who have been harmed by unsafe medical products, including cases involving breast implants associated with lymphoma.
In more detail, the US Food and Drug Administration (FDA) has received reports about women who have had breast implant procedures done and, later, were diagnosed with these medical conditions:
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
- Anaplastic Large Cell Lymphoma (ALCL)
- Non-Hodgkin Lymphoma (also known as Non-Hodgkin’s Lymphoma, NHL, or just Lymphoma)
- T-cell Lymphoma
We encourage you to submit a Breast Implants Cancer Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible breast implants case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
- Summary of Information
- The Disease
- FDA Information
- Frequently Asked Questions
➤ About the Disease
➤ Risk Factors
We are here to help the women and families who have experienced this unfortunate situation. We have successfully handled personal injury and wrongful death cases for people throughout the country.
Our firm does not put its clients into large class actions lawsuits. Rather, an individual lawsuit is filed for each case. There are no costs associated with having us review your possible breast implants case.
Be assured that the information you provide to our law firm is treated as strictly confidential. Submitting a case evaluation does not obligate you to hire our law firm.
Lastly, we want you to know that you will get a reply directly from attorney Tom Lamb no later than the next business day.
Most Recent Article on This Topic
Since our previous article, Allergan Aesthetics Launches Tracking Campaign for U.S. Breast Implant Patients, recent news articles report the majority of American women are unaware of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
Studies on BIA-ALCL Knowledge
According to a July 2020 Practice Update article, 500 women participated in a survey on their baseline knowledge of BIA-ALCL. The study was conducted by Dr. Justin Sacks, Chief of the Division of Plastic and Reconstructive Surgery at Washington University in St. Louis, Missouri, and a member of the American Society of Plastic Surgeons. The research found the following:
The researchers found that 12 percent of respondents had received breast implants and 73 percent knew someone with implants. Of all respondents, 13.6 percent had previously heard of BIA-ALCL; 51.7 percent of respondents with implants had previously heard of BIA-ALCL. Even after receiving information about BIA-ALCL risk, 58.4 percent of respondents were still willing to receive a reconstructive implant and 45.8 percent were willing to receive a cosmetic implant, while 35.8 percent reported they would be less likely to receive an implant. Two-thirds (66.7 percent) of the respondents with breast implants reported some degree of concern regarding BIA-ALCL, while just over one-third (35.0 percent) were strongly considering removing their implants.
To read more of this article, click below:
Similarly, Medical XPress posted an article claiming only 1 out of every 7 American women have even heard of BIA-ALCL. Awareness only increases to just over half for those who have implants. Additionally, the article states:
Most women who had heard of BIA-ALCL got their information through the media and healthcare blogs. “Our findings suggest that professional healthcare blogs and media outlets may be the most effective way to spread knowledge, particularly to those who are not in direct contact with healthcare professionals,” Dr. Sacks and colleagues write.
“Our findings can help surgeons navigate the risks of BIA-ALCL with current and prospective patients and can guide future public education efforts on BIA-ALCL,” Dr. Sacks and coauthors write.[Read article in full at original source]
Our earlier articles about this breast implants lymphoma cancer situation:
- Allergan Aesthetics Launches Tracking Campaign for U.S. Breast Implant Patients
- Advances Made in Understanding and Treatment of BIA-ALCL
- Cancer Linked to Breast Implants: Is it Considered Rare Anymore?
- FDA Proposes New Recommendations for Breast Implant Labels
- TGA Regulations on Breast Implant Products
- FDA Recalls Allergan Textured Implants
- Statistics Show An Increased Risk For BIA-ALCL With Textured Implants
- Textured Breast Implants Ban: Onto Australia
- FDA Fails When It Comes To Banning Textured Breast Implants
- Textured Breast Implants Bans on the Rise
- March 2019 FDA Meeting On Breast Implants: A Summary Of What You Need To Know
- Breast Implants FDA March 2019 Meeting: Lymphoma Cancer Was A Main Topic
- 2019 Discoveries and Warnings on Breast Implant-Associated Lymphoma
- Breast Implants Lymphoma Cancer Cases Update February 2019 – US & Canada
- Allergan Textured Breast Implants Recalled In Europe Due To BIA-ALCL
- FDA Provides Updated Number of Breast Implants Lymphoma Cancers
- New Data Released on Risk of Lymphoma Due to Breast Implants
- Breast Implant-Associated Lymphoma Diagnoses on the Rise
- What is the Risk of Death Due to Breast Implant-Associated Lymphoma?
- Treatments For Breast Implants Associated Lymphoma And Blood Cancer
- Breast Implants and Lymphoma: Who’s to Blame?
- Breast Implants Lymphoma Cancer: Diagnosis And Treatment Developments
- Breast Implant Lymphoma: Causes Uncertain, but Costs Undeniable
- March 2017 FDA Report: Breast Implants Linked To Lymphoma Blood Cancer
- Breast Implants Linked to Rare Lymphoma Blood Cancer